Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

FTSE slides after BOE meeting as pound pops higher

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/08/2018 | 06:08pm CET
A worker shelters from the rain as he passes the London Stock Exchange in London

MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed on big British overseas earners.

The FTSE <.FTSE> was closed 1.5 percent lower at 7,170.69 points. The index is down 6.7 percent in the year to date, making it the worst performer among top European bourses.

The Bank of England said that interest rates probably need to rise sooner and by a bit more than it thought only three months ago, which boosted sterling.

The rise in the currency weighed on the FTSE's predominantly dollar-earning firms, with shares in heavyweight consumer staples British American Tobacco (>> British American Tobacco), Reckitt Benckiser (>> Reckitt Benckiser) and Unilever (>> Unilever) dropping 1.8 percent to 3.2 percent.

"We are growing cautious on those companies which rely heavily on overseas earnings, as rising interest rates could cause the pound to strengthen further from here," Andrew Morgan, portfolio manager of Alpha:r² at Walker Crips, said.

"We continue to be relatively defensively positioned in equities, despite the recent dip, and are looking at certain sectors - such as Financials - which tend to benefit from a rising interest rate environment," Morgan added.

On the day shares in banking stocks RBS (>> Royal Bank of Scotland Group), Barclays (>> Barclays) and Lloyds (>> Lloyds Banking Group) were among the dozen or so stocks in positive territory, up 0.4 percent to 1 percent.

GlaxoSmithKline (>> GlaxoSmithKline) was another riser, up 1.4 percent after U.S. regulators delayed approval of a generic copy from Novartis of its blockbuster Advair lung drug and after the group took legal action against Gilead Sciences (>> Gilead Sciences) over a new HIV drug.

The news helped build confidence after an upbeat results presentation by GlaxoSmithKline on Wednesday. Competitive threats to its respiratory and HIV businesses are seen as key risks for the company's stock.

AstraZeneca (>> AstraZeneca) rose 1.2 percent, boosted by a price target upgrade from Berenberg.

WPP (>> WPP Group) rose 3.1 percent following a reassuring update from French peer Publicis (>> Publicis Groupe), while Compass (>> Compass Group plc), the world's biggest catering firm, jumped more than 5 percent after it raised its expectations for revenue growth.

Their gains however were more than offset by broad-based weakness as markets remained nervous following a sell-off earlier this week triggered by a spike in global yields and volatility.

Miners, along with energy stocks, were a big weight on the FTSE, with the two commodities-related sectors collectively wiping around 40 points off the index, as prices of copper <CMCU3> and other metals fell and oil retreated.

Precious metals miner Randgold (>> Randgold Resources) fell 2.4 percent after HSBC raised its rating on the stock but trimmed its price target. Antofagasta (>> Antofagasta) and BHP Billiton (>> BHP Billiton Plc) were also both down around 2.5 percent.

Among midcaps, Sophos (>> Sophos Ltd) fell 17.5 percent after the cloud services provider reported slower growth in the amount it bills its customers, while TalkTalk (>> TalkTalk Telecom Group) slumped after flagging a dividend cut and a cash call.

(Reporting by Danilo Masoni and Kit Rees; Editing by Peter Graff)

By Danilo Masoni and Kit Rees

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04:39pASTRAZENECA : European indices gain tracking Asian equities
AQ
04:09pMERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
11:08aASTRAZENECA : FDA grants EAP designation to Guardant's NGS-based liquid biopsy
AQ
10:03aASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
AQ
09:15aAstraZeneca's immunotherapy drug wins key lung cancer approval
RE
08:37aASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
DJ
08:01aASTRAZENECA : IMFINZI approved for Stage III nsclc
AQ
02/18ASTRAZENECA : lung cancer drug gets OK from FDA
AQ
02/17ASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
PU
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
More news
News from SeekingAlpha
09:21aAstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
02/18BioSci Rounds Report For Feb. 16, 2018 
02/17FDA OKs expanded use for AstraZeneca's Imfinzi 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16AstraZeneca (AZN) Presents At Leerink Partners 7th Annual Global Healthcare C.. 
Financials ($)
Sales 2018 22 314 M
EBIT 2018 5 619 M
Net income 2018 2 143 M
Debt 2018 13 859 M
Yield 2018 4,13%
P/E ratio 2018 34,64
P/E ratio 2019 27,18
EV / Sales 2018 4,40x
EV / Sales 2019 4,14x
Capitalization 84 269 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,7 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-7.96%83 544
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572